Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002095 · ClinicalTrials.gov registry record · NA
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
A NA study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- NA
- Development phase
- 700
- Enrollment target
NCT00002095: Completed NA study, sponsored by Hoffmann-La Roche.
NCT00002095 is a NA study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 700 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002095, a NA study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- NA
- Development phase
- 700 participants
- Enrollment target
Study Summary
To evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (CMV) disease (e.g., CMV retinitis, gastrointestinal CMV disease) in CMV-infected people with HIV infection and CD4 lymphocyte counts \<= 100 cells/mm3. To evaluate the efficacy of this drug in reducing morbidity associated with coinfection by both CMV and HIV.
Interventions
- DRUG Ganciclovir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Phase | NA |
What the finished NCT00002095 record still lists
NCT00002095 is an interventional study that assigns participants to a tested intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which Ganciclovir is the first listed.
NCT00002095 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002095 about?
NCT00002095 is a clinical study titled "A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus". To evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (CMV) disease (e.g., CMV retinitis, gastrointestinal CMV disease) in CMV-infected people with HIV infection and CD4 lymphocyte counts \<= 100 cells/mm3. To evaluate the efficacy of this drug in reducing morbidi...
What is the current status of trial NCT00002095?
This trial is currently completed. It is a NA study. The enrollment target is 700 participants.
What interventions are being tested in trial NCT00002095?
The interventions under investigation include: Ganciclovir (DRUG).
Who is sponsoring clinical trial NCT00002095?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002095's enrollment target sits among peer trials
700 149th of 2000 higher than 1,850 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients